2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

3503 TP53 mutations define a high-risk subgroup in follicular lymphoma and enhance FLIPI-based risk stratification

Davidson Zhao, Verena Passerini, PhD2, Victoria Buse Shelton, MSc3, Rohan Khan4, Entsar Eladl5, Ting Liu, PhD6, Kacie Smith7, Findlay Bewicke-Copley, PhD, MSc, BSc8, Maja Ludvigsen, PhD9, Francesco d'Amore, MD10, Marianne Brodtkorb11, Nathalie Johnson, MD12, Tara Baetz, MD13, David LeBrun14, Josh W.D Tobin, MD, PhD15, Maher K Gandhi, MD PhD16, Christian Steidl, MD17, Rosemarie Tremblay-LeMay18, Michael Crump, MD19, Anca Prica, MD20, John Kuruvilla, MD21, David Hodgson, MD, MPH22, Brad S. Kahl, MD23, Andrew Evens I, DO,MBA, MSc24, Hong Chang, MD25, Jessica Okosun, PhD, FRCPath, MBBChir26, Oliver Weigert, MD27, Robert Kridel, MD28
1 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto Medical Biophysics, Toronto, Ontario, Canada
2 Ludwig-Maximilians-University Hospital, Munich, Germany
3 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
4 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
5 University Health Network, Toronto, Canada
6 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
7 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
8 Barts Cancer Institute - Queen Mary University of London, London, United Kingdom
9 Aarhus University Hospital, Aarhus, Denmark, Aarhus University, Aarhus, Denmark
10 Aarhus University, Aarhus, Denmark
11 Oslo University Hospital, Oslo, Norway
12 Jewish General Hospital, Montreal, Canada
13 BC Cancer Victoria - University of British Columbia, Victoria, Canada
14 Queen’s University, Kingston, Canada
15 Mater Research Institute - University of Queensland, Brisbane, Australia, Princess Alexandra Hospital, Brisbane, Australia
16 Princess Alexandra Hospital, Brisbane, Australia
17 BC Cancer, Vancouver, Canada
18 University Health Network, Toronto, Canada
19 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
20 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
21 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
22 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
23 Washington University, St. Louis, United States
24 Rutgers Cancer Institute, New Brunswick, United States
25 University Health Network, Toronto, Canada
26 Barts Cancer Institute - Queen Mary University of London, London, United Kingdom
27 Ludwig-Maximilians-University Hospital, Munich, Germany
28 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto Medical Biophysics, Toronto, Ontario, Canada

Introduction

Despite advances in the genomic characterization of follicular lymphoma (FL), the prognostic role of TP53 mutations is incompletely defined. The prevalence of TP53 mutations varies across studies and their prognostic impact, particularly when considered alongside established clinical risk models, remains uncertain. While TP53 status is a key determinant of risk stratification and therapeutic decision-making in other indolent B-cell malignancies, such as chronic lymphocytic leukemia, its significance in FL may be underappreciated. These gaps prompted us to systematically evaluate the clinical relevance of TP53 mutations in a large, clinically annotated FL cohort.

Methods

We analyzed a multicentre cohort of 1,723 adult patients with newly diagnosed FL from 15 institutions or clinical trials. Patients received heterogenous first-line management, including watch and wait (WW), radiotherapy and chemoimmunotherapy. Hybridization-based targeted DNA sequencing data covering recurrently mutated genes in FL, including the full coding region of TP53, were available for all cases. Variants with allele fractions greater than 10% were considered for analysis. Matched sequencing data from samples obtained at the time of transformation (T2, n=124) were also available. Immunohistochemistry (IHC) for p53 was performed on matched samples collected at baseline (n=203) and at transformation (n=84).

Results

A total of 124 TP53 mutations were detected in 119 (7%) patients at baseline. The majority of TP53 mutations were missense mutations affecting the p53 DNA binding domain (86/124, 69%). We identified frequent missense mutations at hotspot positions R248 (n=12), R175 (n=7) and R273 (n=5). Among patients with mutational profiling at both baseline and transformation, the frequency of TP53 mutations was increased in T2 samples (31% vs 12%; P < 0.001). For patients with TP53 mutations at baseline, the majority (80%) had detectable TP53 variants at the time of transformation, with an increase in VAF observed in the T2 sample (median: 57% vs 25%; P < 0.001).

TP53 mutations were associated with grade 3A (23% vs 11%, P = 0.002), but not with age, sex or stage. TP53-mutated FL was associated with progression of disease within 24 months (35% vs 19%, P < 0.001), inferior PFS (HR = 1.79; median 43.8 vs 92.0 months; P < 0.001) and inferior time to transformation (TTT) (HR = 2.07; median 68.2 vs 200.9 months; P = 0.002). No significant association with OS was observed (HR = 1.27; median not reached; P = 0.18). The inferior PFS and TTT associated with TP53 mutations was observed across all evaluable treatment groups including WW, radiotherapy and chemoimmunotherapy (PFS: HR range = 1.60-1.93 and TTT: HR range = 1.74-2.56). Within FLIPI subgroups, TP53 mutations were enriched in high-risk patients compared to low/intermediate-risk patients (9.1% vs 5.3%, P = 0.012) and were associated with inferior PFS and TTT in high-risk patients (PFS: HR = 2.02; median 40.0 vs 89.5 months; P < 0.001 and TTT: HR = 3.91; median 26.9 vs 200.9 months; P < 0.001), but not in intermediate- or low-risk patients.

p53 IHC enabled quantification of cells based on strong, moderate and weak staining. TP53 mutations were associated with increased proportion of cells with strong staining (median: 23% vs 2%; P < 0.001) and moderate staining (median: 14% vs 3%; P < 0.001), and to a lesser extent weak staining (median: 9% vs 7%; P = 0.048). Missense TP53 mutations were associated with increased strong p53 IHC staining compared to all other variant types (median: 25% vs 2%; P = 0.010). The variant allele fraction of missense TP53 mutations was correlated with the proportion of strongly staining cells (R = 0.53, P < 0.001). At baseline, strong staining in >20% cells was associated with inferior PFS (HR = 2.21; median 10.4 vs 43.0 months; P = 0.020).

Conclusions

TP53 mutations define a subgroup of FL patients with markedly inferior outcomes, characterized by an approximately two-fold worse PFS. Moreover, the integration of TP53 mutation status with FLIPI enhances risk stratification particularly in the high-risk FLIPI group. p53 IHC may serve as a practical surrogate for TP53 mutations however incompletely captures the full spectrum of TP53 mutations. Our findings support incorporation of TP53 status into clinical risk assessment in FL and identify a high-risk subgroup that may benefit from novel therapies.

Davidson Zhao: No relevant conflicts of interest to declare.